BR112018069461A2 - nova forma cristalina de sal de 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina salt - Google Patents

nova forma cristalina de sal de 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina salt

Info

Publication number
BR112018069461A2
BR112018069461A2 BR112018069461-4A BR112018069461A BR112018069461A2 BR 112018069461 A2 BR112018069461 A2 BR 112018069461A2 BR 112018069461 A BR112018069461 A BR 112018069461A BR 112018069461 A2 BR112018069461 A2 BR 112018069461A2
Authority
BR
Brazil
Prior art keywords
crystalline form
salt
pyrrol
sulfonyl
methoxy
Prior art date
Application number
BR112018069461-4A
Other languages
English (en)
Inventor
Kim Aeri
Hyung Cho Kwan
Original Assignee
Daewoong Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co., Ltd. filed Critical Daewoong Pharmaceutical Co., Ltd.
Publication of BR112018069461A2 publication Critical patent/BR112018069461A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

a presente invenção proporciona uma nova forma cristalina i de cloridrato, uma forma cristalina ii de cloridrato, uma forma cristalina de succinato, uma forma cristalina de tartrato, uma forma cristalina i de fumarato e uma forma cristalina ii de fumarato de 1?(5?(2,4?difluorfenil)?1?((3?fluorfenil)sulfonil)?4?metoxi?1h?pirrol?3?il)?n?metilmetanamina. as novas formas cristalinas descritas acima têm alta solubilidade em água e excelente estabilidade sob condições à prova de umidade e sob condições de alta exposição à umidade e, portanto, podem ser usadas farmaceuticamente.
BR112018069461-4A 2016-03-25 2017-03-17 nova forma cristalina de sal de 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina salt BR112018069461A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020160036080A KR102081920B1 (ko) 2016-03-25 2016-03-25 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR10-2016-0036080 2016-03-25
PCT/KR2017/002914 WO2017164576A1 (en) 2016-03-25 2017-03-17 Novel crystalline form of 1-(5-(2,4-difluorophenyl)-l-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n- methylmethanamine salt

Publications (1)

Publication Number Publication Date
BR112018069461A2 true BR112018069461A2 (pt) 2019-02-12

Family

ID=59900401

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018069461-4A BR112018069461A2 (pt) 2016-03-25 2017-03-17 nova forma cristalina de sal de 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina salt

Country Status (32)

Country Link
US (6) US10336695B2 (pt)
EP (1) EP3433233B1 (pt)
JP (1) JP6554617B2 (pt)
KR (1) KR102081920B1 (pt)
CN (1) CN108602772B (pt)
AR (1) AR107963A1 (pt)
AU (1) AU2017238918B2 (pt)
BR (1) BR112018069461A2 (pt)
CA (1) CA3014745C (pt)
CL (3) CL2018002416A1 (pt)
CO (1) CO2018008833A2 (pt)
DO (1) DOP2018000190A (pt)
EA (1) EA029995B1 (pt)
ES (1) ES2818902T3 (pt)
HK (1) HK1254393A1 (pt)
HR (1) HRP20201594T1 (pt)
HU (1) HUE053502T2 (pt)
JO (1) JOP20170070B1 (pt)
MA (1) MA43833B1 (pt)
MX (1) MX2018009219A (pt)
MY (1) MY196299A (pt)
NZ (1) NZ745266A (pt)
PE (1) PE20190170A1 (pt)
PH (1) PH12018501846A1 (pt)
PL (1) PL3433233T3 (pt)
PT (1) PT3433233T (pt)
RS (1) RS60884B1 (pt)
SG (1) SG11201806966SA (pt)
SI (1) SI3433233T1 (pt)
TN (1) TN2018000288A1 (pt)
TW (1) TWI626234B (pt)
WO (1) WO2017164576A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102081920B1 (ko) 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR102233456B1 (ko) * 2017-05-31 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102233455B1 (ko) * 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102126576B1 (ko) * 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
AU2020409932B2 (en) * 2019-12-18 2023-09-07 Daewoong Pharmaceutical Co., Ltd. Liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrole-3-yl)-N-methylmethaneamine
CN117820193A (zh) * 2022-09-29 2024-04-05 安徽皓元药业有限公司 一种非苏拉赞盐酸盐晶型a及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2402362T3 (es) 2004-09-30 2013-05-03 Takeda Pharmaceutical Company Limited Inhibidores de la bomba de protones
ME00610B (me) * 2005-08-30 2011-12-20 Takeda Pharmaceuticals Co 1 –heterociklilsulfonil, 2 –aminometil, 5– (hetero–) aril supstituisan 1–h–pirol derivati kao inhibitori lučenja kiseline
WO2007114338A1 (ja) * 2006-03-31 2007-10-11 Takeda Pharmaceutical Company Limited 酸分泌抑制薬
WO2008036211A1 (en) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety
US8933105B2 (en) * 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
EP2921479B1 (en) 2012-11-19 2017-02-01 Jiangsu Hansoh Pharmaceutical Co., Ltd. Pyrrole sulfonamide derivative, preparation method for same, and medical application thereof
KR102084185B1 (ko) 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
CN106957252B (zh) * 2014-11-19 2019-11-19 连云港恒运药业有限公司 一种质子泵抑制剂中间体及其制备方法
CN104447491B (zh) * 2014-11-19 2017-06-23 连云港恒运医药有限公司 含吡咯环质子泵抑制剂的半富马酸盐及其中间体和医药用途
KR101613245B1 (ko) * 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR102081920B1 (ko) 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR20170113040A (ko) 2016-03-25 2017-10-12 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염
KR102233456B1 (ko) 2017-05-31 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102233455B1 (ko) 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법

Also Published As

Publication number Publication date
PH12018501846B1 (en) 2019-05-15
US20200123106A1 (en) 2020-04-23
PT3433233T (pt) 2020-08-03
AU2017238918A8 (en) 2018-08-30
US10889545B2 (en) 2021-01-12
CL2020000186A1 (es) 2020-08-07
US10913715B2 (en) 2021-02-09
EP3433233A4 (en) 2019-08-14
CN108602772B (zh) 2021-06-04
CL2020001826A1 (es) 2020-12-11
ES2818902T3 (es) 2021-04-14
TN2018000288A1 (en) 2020-01-16
SG11201806966SA (en) 2018-09-27
CA3014745C (en) 2020-04-28
EA029995B1 (ru) 2018-06-29
CN108602772A (zh) 2018-09-28
HK1254393A1 (zh) 2019-07-19
KR102081920B1 (ko) 2020-02-26
CA3014745A1 (en) 2017-09-28
MX2018009219A (es) 2018-09-10
PE20190170A1 (es) 2019-02-01
DOP2018000190A (es) 2018-09-30
JP2019509308A (ja) 2019-04-04
EP3433233B1 (en) 2020-07-22
TWI626234B (zh) 2018-06-11
EP3433233A1 (en) 2019-01-30
PL3433233T3 (pl) 2020-12-14
WO2017164576A1 (en) 2017-09-28
US20200181082A1 (en) 2020-06-11
US11459297B2 (en) 2022-10-04
EA201790454A2 (ru) 2017-09-29
TW201736343A (zh) 2017-10-16
JP6554617B2 (ja) 2019-07-31
MY196299A (en) 2023-03-24
AR107963A1 (es) 2018-07-04
JOP20170070B1 (ar) 2021-08-17
US20190322622A1 (en) 2019-10-24
CL2018002416A1 (es) 2018-12-28
PH12018501846A1 (en) 2019-05-15
US10336695B2 (en) 2019-07-02
RS60884B1 (sr) 2020-11-30
NZ745266A (en) 2020-03-27
AU2017238918A1 (en) 2018-08-16
US20190047953A1 (en) 2019-02-14
HUE053502T2 (hu) 2021-07-28
WO2017164576A8 (en) 2018-08-09
US20210139424A1 (en) 2021-05-13
AU2017238918B2 (en) 2019-05-09
US10683268B2 (en) 2020-06-16
HRP20201594T1 (hr) 2020-12-11
EA201790454A3 (ru) 2017-11-30
SI3433233T1 (sl) 2020-10-30
KR20170111170A (ko) 2017-10-12
CO2018008833A2 (es) 2018-09-28
US20230159454A1 (en) 2023-05-25
US11858894B2 (en) 2024-01-02
MA43833B1 (fr) 2020-08-31

Similar Documents

Publication Publication Date Title
BR112018069461A2 (pt) nova forma cristalina de sal de 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina salt
EA201991697A1 (ru) Сульфоксиминовые ингибиторы гликозидазы
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
BR112017006251A2 (pt) novos compostos
MX2022009998A (es) Formas cristalinas de la n-(4-(4-(ciclopropilmetil)piperazin-1- carbonil)fenil)quinolin-8-sulfonamida.
EA202090413A1 (ru) Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
EA201390877A1 (ru) Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение
EA201070871A1 (ru) Бициклические производные азабициклических карбоксамидов, их получение и их применение в терапии
HK1254394A1 (zh) 1-(5-(2，4-二氟苯基)-1-((3-氟苯基)磺酰基)-4-甲氧基-1h-吡咯-3-基)-n-甲基甲胺的新酸加成鹽
PE20220569A1 (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y metodos de tratamiento con dichos compuestos
EA201100035A1 (ru) Производные тиазолилпиперидина
MX2020002505A (es) Compuestos heteroaromaticos sustituidos con cicloolefinas y su uso.
EA201891736A1 (ru) Сокристалл
EA201892425A1 (ru) Гетероциклические амиды, пригодные в качестве модуляторов белков
EA202091277A1 (ru) Кристаллические формы n-(4-(4-(циклопропилметил)пиперазин-1-карбонил)фенил)хинолин-8-сульфонамида
EA202190213A1 (ru) Производные 3-(5-гидрокси-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и их применение в лечении заболеваний, связанных с белком с "цинковыми пальцами" 2 (ikzf2) семейства ikaros
UA127755U (uk) Поліетергуанідингідрохлорид як бактерицидна речовина
AR107062A1 (es) Compuestos heteroaromáticos como inhibidores de btk
EA201990686A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
TH174565B (th) อนุพันธ์เตตระไฮโดรไพรานิล เบนซาไมด์
WO2015131021A3 (en) Anti-amyloid compounds containing benzofurazan

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]